|
gptkbp:instanceOf
|
gptkb:drug
stimulant
phenethylamine derivative
|
|
gptkbp:abusePotential
|
high
|
|
gptkbp:approvalYear
|
2001
|
|
gptkbp:approvedBy
|
gptkb:United_States
|
|
gptkbp:ATCCode
|
N06BA23
|
|
gptkbp:brand
|
gptkb:Focalin
|
|
gptkbp:CASNumber
|
564-02-3
|
|
gptkbp:contraindication
|
anxiety
glaucoma
tics
|
|
gptkbp:controlledSubstanceSchedule
|
gptkb:Schedule_II_(US)
|
|
gptkbp:developedBy
|
gptkb:Novartis
|
|
gptkbp:drugClass
|
stimulant
norepinephrine reuptake inhibitor
|
|
gptkbp:eliminationHalfLife
|
2-4 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:form
|
extended-release capsule
immediate-release tablet
|
|
gptkbp:hasEnantiomer
|
gptkb:methylphenidate
|
|
gptkbp:hasMolecularFormula
|
C14H19NO2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Dexmethylphenidate
|
|
gptkbp:IUPACName
|
(R)-methyl 2-phenyl-2-(2-piperidyl)acetate
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
norepinephrine reuptake inhibitor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescribes
|
adolescents
adults
children
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1201202
115200
103070
|
|
gptkbp:relatedTo
|
gptkb:lisdexamfetamine
gptkb:methylphenidate
amphetamine
ritalin
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
headache
increased heart rate
insomnia
dry mouth
decreased appetite
|
|
gptkbp:synonym
|
gptkb:d-methylphenidate
d-threo-methylphenidate
|
|
gptkbp:UNII
|
I9W7N6B1K2
|
|
gptkbp:usedFor
|
gptkb:attention_deficit_hyperactivity_disorder
|
|
gptkbp:bfsParent
|
gptkb:Schedule_II
|
|
gptkbp:bfsLayer
|
6
|